Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Jurcic, JG; Raza, A; Vlad, G; Stein, EM; Roshal, M; Bixby, DL; Boyer, DF; Vigil, CE; Syrbu, S; Sekeres, MA; Rogers, HJ; Rizzieri, DA; Lagoo, AS; Roboz, GJ; Redner, RL; Steensma, DP; Cook, RJ; Moyo, T; McKeown, M; Waters, NJ; Stephens, K; Volkert, A; Di Tomaso, E; Roth, DA; Cortes, JE

Published Date

  • December 7, 2017

Published In

Volume / Issue

  • 130 /

Published By


  • 3

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 59th Annual Meeting of the American-Society-of-Hematology (ASH)

Conference Location

  • Atlanta, GA

Conference Start Date

  • December 9, 2017

Conference End Date

  • December 12, 2017